Clinical Report: Targeting Specific and General Effects of Intermittent Theta-Burst Stimulation in Depression Treatment
Overview
This study evaluates the efficacy of intermittent theta-burst stimulation (iTBS) in treating major depressive disorder (MDD) compared to sham stimulation. iTBS showed greater short-term reductions in depressive symptoms, but differences were not sustained at the 4-week follow-up.
Background
Major depressive disorder (MDD) is a leading cause of disability worldwide, with many patients not achieving sufficient improvement through traditional therapies. Repetitive transcranial magnetic stimulation (rTMS), particularly iTBS, has emerged as a promising alternative due to its comparable efficacy and shorter treatment times.
Data Highlights
Measure
iTBS
Sham
MADRS Improvement (Day 5)
Greater
Less
MADRS Improvement (Day 10)
Greater
Less
Response Rate
39.5%
22.6%
Remission Rate
34.2%
22.6%
Key Findings
Active iTBS resulted in greater MADRS score improvements at midtreatment and posttreatment compared to sham.
No significant differences in response or remission rates were observed between iTBS and sham at the end of treatment.
The trial was likely underpowered to detect categorical outcomes.
Adverse effects were mild and transient.
Discordance between clinician-rated and self-reported measures of depressive symptoms was noted.
Clinical Implications
The findings indicate that iTBS can provide short-term symptom relief in MDD. Further research is needed to explore the effects of treatment duration and the role of expectancy in clinical outcomes.
Conclusion
This study highlights the efficacy of iTBS in the short-term treatment of MDD. Future trial designs should address blinding integrity and the assessment of expectancy effects.
